1. |
Adamus G. Importance of autoimmune responses in progression of retinal degeneration initiated by gene mutations[J/OL]. Front Med (Lausanne), 2021, 8: 672444[2021-12-02]. https://pubmed.ncbi.nlm.nih.gov/34926479/. DOI: 10.3389/fmed.2021.672444.
|
2. |
Braithwaite T, Holder GE, Lee RW, et al. Diagnostic features of the autoimmune retinopathies[J]. Autoimmun Rev, 2014, 13(4-5): 534-538. DOI: 10.1016/j.autrev.2014.01.039.
|
3. |
Ten Berge JC, Fazil Z, van den Born I, et al. Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract[J]. Acta Ophthalmologica, 2019, 97(2): 185-192. DOI: 10.1111/aos.13899.
|
4. |
Wildner G. Tumors, tumor therapies, autoimmunity and the eye[J/OL]. Autoimmun Rev, 2021, 20(9): 102892[2021-07-13]. https://pubmed.ncbi.nlm.nih.gov/34229046/. DOI: 10.1016/j.autrev.2021.102892.
|
5. |
陈玥, 姜利斌. 自身免疫性视网膜病变的临床特征与研究进展[J]. 中华眼底病杂志, 2021, 37(11): 901-905. DOI: 10.3760/cma.j.cn511434-20201112-00547.Chen Y, Jiang LB. Clinical features and research progress of autoimmune retinopathy[J]. Chin J Ocul Fundus Dis, 2021, 37(11): 901-905. DOI: 10.3760/cma.j.cn511434-20201112-00547.
|
6. |
Chen M, Luo C, Zhao J, et al. Immune regulation in the aging retina[J]. Prog Retin Eye Res, 2019, 69: 159-172. DOI: 10.1016/j.preteyeres.2018.10.003.
|
7. |
Morohoshi K, Goodwin AM, Ohbayashi M, et al. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration[J]. J Autoimmun, 2009, 33(3-4): 247-254. DOI: 10.1016/j.jaut.2009.09.003.
|
8. |
McMurtrey JJ, Tso MOM. A review of the immunologic findings observed in retinitis pigmentosa[J]. Surv Ophthalmol, 2018, 63(6): 769-781. DOI: 10.1016/j.survophthal.2018.03.002.
|
9. |
Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. Molecular mimicry and autoimmunity[J]. J Autoimmun, 2018, 95: 100-123. DOI: 10.1016/j.jaut.2018.10.012.
|
10. |
Adamus G. Impact of autoantibodies against glycolytic enzymes on pathogenicity of autoimmune retinopathy and other autoimmune disorders[J/OL]. Front Immunol, 2017, 8: 505[2017-04-28]. https://pubmed.ncbi.nlm.nih.gov/28503176/. DOI: 10.3389/fimmu.2017.00505.
|
11. |
Adamus G, Yang S, Weleber RG. Unique epitopes for carbonic anhydrase Ⅱ autoantibodies related to autoimmune retinopathy and cancer-associated retinopathy[J]. Exp Eye Res, 2016, 147: 161-168. DOI: 10.1016/j.exer.2016.05.012.
|
12. |
Adamus G. Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer[J]. Invest Ophthalmol Vis Sci, 2015, 56(3): 1680-1688. DOI: 10.1167/iovs.14-15739.
|
13. |
Hara M, Martinez-Hernandez E, Ariño H, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor[J/OL]. Neurology, 2018, 90(16): e1386-e1394[2018-03-16]. https://pubmed.ncbi.nlm.nih.gov/29549218/. DOI: 10.1212/WNL.0000000000005329.
|
14. |
Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy[J]. J Autoimmun, 2009, 32(2): 133-139. DOI: 10.1016/j.jaut.2009.02.001.
|
15. |
Ladewig G, Reinhold U, Thirkill CE, et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on cancer stage I-IV[J]. Br J Dermatol, 2005, 152(5): 931-938. DOI: 10.1111/j.1365-2133.2005.06480.x.
|
16. |
Adamus G, Champaigne R, Yang S. Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy[J/OL]. Clin Immunol, 2020, 210: 108317[2019-11-23]. https://pubmed.ncbi.nlm.nih.gov/31770612/. DOI: 10.1016/j.clim.2019.108317.
|
17. |
Angeletti A, Migliorini P, Bruschi M, et al. Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms[J/OL]. Autoimmun Rev, 2021, 20(12): 102977[2021-10-27]. https://pubmed.ncbi.nlm.nih.gov/34718161/. DOI: 10.1016/j.autrev.2021.102977.
|
18. |
Przeździecka-Dołyk J, Brzecka A, Ejma M, et al. Ocular paraneoplastic syndromes[J/OL]. Biomedicines, 2020, 8(11): 490[2020-11-10]. https://pubmed.ncbi.nlm.nih.gov/33182708/. DOI: 10.3390/biomedicines8110490.
|
19. |
|
20. |
Chen JJ, McKeon A, Greenwood TM, et al. Clinical utility of antiretinal antibody testing[J]. JAMA Ophthalmol, 2021, 139(6): 658-662. DOI: 10.1001/jamaophthalmol.2021.0651.
|
21. |
Nikoopour E, Lin CM, Sheskey S, et al. Immune cell infiltration into the eye is controlled by IL-10 in recoverin-Induced autoimmune retinopathy[J]. J Immunol, 2019, 202(4): 1057-1068. DOI: 10.4049/jimmunol.1800574.
|
22. |
Sen HN, Grange L, Akanda M, et al. Autoimmune retinopathy: current concepts and practices (an American ophthalmological society thesis)[J/OL]. Trans Am Ophthalmol Soc, 2018, 115: T8[2017-03-08]. https://pubmed.ncbi.nlm.nih.gov/29576753/.
|
23. |
Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review[J]. Retina, 2014, 34(5): 827-845. DOI: 10.1097/IAE.0000000000000119.
|
24. |
Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy[J]. Autoimmun Rev, 2009, 8(5): 410-414. DOI: 10.1016/j.autrev.2009.01.002.
|
25. |
Safadi K, Chowers I, Banin E, et al. Autoimmune retinopathy: clinical, electrophysiological, and immunological features in nine patients with long-term follow-up[J]. Graefe's Arch Clin Exp Ophthalmol, 2022, 260(3): 975-991. DOI: 10.1007/s00417-021-05409-4.
|
26. |
Pawestri AR, Arjkongharn N, Suvannaboon R, et al. Autoantibody profiles and clinical association in Thai patients with autoimmune retinopathy[J/OL]. Sci Rep, 2021, 11(1): 15047[2021-07-22]. https://pubmed.ncbi.nlm.nih.gov/34294798/. DOI: 10.1038/s41598-021-94377-0.
|
27. |
Haapasalo J, Nordfors K, Haapasalo H, et al. The expression of carbonic anhydrases Ⅱ, Ⅸ and Ⅻ in brain tumors[J//OL]. Cancers (Basel), 2020, 12(7): 1723[2020-06-29]. https://pubmed.ncbi.nlm.nih.gov/32610540/. DOI: 10.3390/cancers12071723.
|
28. |
Davoudi S, Ebrahimiadib N, Yasa C, et al. Outcomes in autoimmune retinopathy patients treated with Rituximab[J]. Am J Ophthalmol, 2017, 180: 124-132. DOI: 10.1016/j.ajo.2017.04.019.
|
29. |
Fox AR, Gordon LK, Heckenlively JR, et al. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified delphi approach[J]. Am J Ophthalmol, 2016, 168: 183-190. DOI: 10.1016/j.ajo.2016.05.013.
|
30. |
Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration[J]. Nat Rev Dis Primers, 2021, 7(1): 31. DOI: 10.1038/s41572-021-00265-2.
|
31. |
Allingham MJ, Loksztejn A, Cousins SW, et al. Immunological aspects of age-related macular degeneration[J]. Adv Exp Med Biol, 2021, 1256: 143-189. DOI: 10.1007/978-3-030-66014-7_6.
|
32. |
Kubicka-Trząska A, Wilańska J, Romanowska-Dixon B, et al. Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration[J/OL]. Acta Ophthalmol, 2014, 92(8): e610-e614[2014-05-06].https://pubmed.ncbi.nlm.nih.gov/24802549/. DOI: 10.1111/aos.12435.
|
33. |
Liu Y, Bell BA, Song Y, et al. Deuterated docosahexaenoic acid protects against oxidative stress and geographic atrophy-like retinal degeneration in a mouse model with iron overload[J/OL]. Aging Cell, 2022: e13579[2022-03-08].https://pubmed.ncbi.nlm.nih.gov/35257475/. DOI: 10.1111/acel.13579.
|
34. |
Gu J, Pauer GJ, Yue X, et al. Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers[J]. Mol Cell Proteomics, 2009, 8(6): 1338-1349. DOI: 10.1074/mcp.M800453-MCP200.
|
35. |
Hollyfield JG, Perez VL, Salomon RG. A hapten generated from an oxidation fragment of docosahexaenoic acid is sufficient to initiate age-related macular degeneration[J]. Mol Neurobiol, 2010, 41(2-3): 290-298. DOI: 10.1007/s12035-010-8110-z.
|
36. |
Morohoshi K, Patel N, Ohbayashi M, et al. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization[J]. Exp Mol Pathol, 2012, 92(1): 64-73. DOI: 10.1016/j.yexmp.2011.09.017.
|
37. |
Adamus G. Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?[J]. Autoimmun Rev, 2017, 16(3): 231-236. DOI: 10.1016/j.autrev.2017.01.005.
|
38. |
刘红丽, 吴继红. 视网膜色素变性的诊断和治疗进展[J]. 中华眼底病杂志, 2021, 37(11): 896-900. DOI: 10.3760/cma.j.cn511434-20210319-00147.Liu HL, Wu JH. Progress in diagnosis and treatment of retinitis pigmentosa[J]. Chin J Ocul Fundus Dis, 2021, 37(11): 896-900. DOI: 10.3760/cma.j.cn511434-20210319-00147.
|
39. |
Sato T, Nishiguchi KM, Fujita K, et al. Serum anti-recoverin antibodies is found in elderly patients with retinitis pigmentosa and cancer[J/OL]. Acta Ophthalmol, 2020, 98(6): e722-e729[2020-02-11]. https://pubmed.ncbi.nlm.nih.gov/32043815/. DOI: 10.1111/aos.14373.
|
40. |
Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa[J]. Am J Ophthalmol, 1999, 127(5): 565-573. DOI: 10.1016/s0002-9394(98)00446-2.
|